Physician profile
Mary E Patterson
NPI 1912112020
$4,361.56
in general payments reported to CMS, 2019-2025
26 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $270 · 2021: $125 · 2023: $465 · 2024: $1,038 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.96 | 2019-2025 | Sogroya, Wegovy |
| Abbvie INC. | $425.02 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $376.44 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $330.68 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $266.56 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $248.13 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $238.96 | 2023-2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $231.77 | 2023-2025 | Triptodur, Triptodur |
| Ipsen Biopharmaceuticals, INC | $189.53 | 2019 | |
| Tolmar, INC. | $179.29 | 2024-2025 | Fensolvi |
| Companion Medical, INC. | $157.17 | 2019-2020 | |
| Eton Pharmaceuticals, INC. | $144.09 | 2024-2025 | Alkindi, Increlex, Khindivi |
| Sanofi-Aventis U.S. LLC | $140.53 | 2024 | |
| Ascendis Pharma Endocrinology INC | $114.81 | 2024-2025 | Skytrofa |
| Arbor Pharmaceuticals, INC. | $101.64 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.13 | 2025 | |
| Kyowa Kirin, INC. | $75.90 | 2024-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $68.69 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $64.77 | 2025 | |
| Lilly USA, LLC | $52.45 | 2019-2020 | |
| Medtronic, INC. | $31.95 | 2023 | Minimed 780g |
| Becton, Dickinson and Company | $27.33 | 2019 | |
| Sandoz INC. | $21.78 | 2019 | |
| Ibsa Pharma INC. | $17.37 | 2019 | |
| Soleno Therapeutics, INC. | $14.61 | 2025 | Vykat Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.